Clinical efficacy of immunotherapy combined with targeted therapy for postoperative recur-rent hepatocellular carcinoma / 中华消化外科杂志
Chinese Journal of Digestive Surgery
; (12): 41-44, 2022.
Article
en Zh
| WPRIM
| ID: wpr-990605
Biblioteca responsable:
WPRO
ABSTRACT
Systemic therapy is the preferred treatment option for advanced primary hepatic carcinoma, and the results of clinical study IMbrave150 suggesting the superiority of atezolizumab combined with bevacizumab for the treatment of hepatocellular carcinoma. The authors introduce the clinical experience of one patient with postoperative recurrent primary hepatic carcinoma who was treated with atezolizumab plus bevacizumab followed by radiotherapy. The results reveal that the efficacy as stable disease during immunotherapy combination of targeted therapy and partial response after radiotherapy, and the patient tolerating well with a high quality of life.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Digestive Surgery
Año:
2022
Tipo del documento:
Article